Legal Representation
Attorney
Michelle E. Tochtrop
USPTO Deadlines
Next Deadline
329 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2016-06-28)
Due Date
June 28, 2026
Grace Period Ends
December 28, 2026
Application History
47 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jul 8, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Jul 8, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Jul 8, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Jul 8, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Jul 8, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Jun 28, 2025 | REM2 | E | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | Loading... |
Dec 10, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Dec 10, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Dec 10, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Dec 10, 2024 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
Dec 10, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Dec 10, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Dec 10, 2024 | EWOR | I | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | Loading... |
Jul 3, 2023 | NAS8 | E | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | Loading... |
Jul 3, 2023 | 8.OK | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED | Loading... |
Jun 20, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
Feb 7, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Feb 7, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Feb 7, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Dec 27, 2022 | ES8R | I | TEAS SECTION 8 RECEIVED | Loading... |
Jun 28, 2021 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
Oct 31, 2016 | COC. | O | CORRECTION UNDER SECTION 7 - PROCESSED | Loading... |
Oct 31, 2016 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
Aug 1, 2016 | I | PAPER RECEIVED | Loading... | |
Aug 1, 2016 | AMD7 | I | SEC 7 REQUEST FILED | Loading... |
Jun 28, 2016 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Apr 12, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Apr 12, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Mar 23, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Mar 9, 2016 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Mar 2, 2016 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Mar 2, 2016 | ALIE | A | ASSIGNED TO LIE | Loading... |
Mar 2, 2016 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Mar 2, 2016 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Mar 2, 2016 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
Mar 2, 2016 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Jan 28, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jan 28, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jan 26, 2016 | ALIE | A | ASSIGNED TO LIE | Loading... |
Jan 13, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Oct 30, 2015 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Oct 30, 2015 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Oct 30, 2015 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Oct 29, 2015 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jul 25, 2015 | MPMK | E | NOTICE OF PSEUDO MARK E-MAILED | Loading... |
Jul 24, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Jul 23, 2015 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; Pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; Pharmaceutical products containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; Pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, including, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; Microbial and biological preparations for improving the physical well-being of humans, namely, reducing inflammation and pain; Supplements, namely, dietary supplements, for medical use and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; Supplements, namely, dietary supplements for medical use and baby food, all the above containing liquid, solid, dried or freeze-dried microorganisms or concentrated cultures of probiotic microorganisms; ferments for medical purposes, all the foregoing being for medical and veterinary use only
Additional Information
Other
In the statement, line 19, "containing microorganisms and cultures of microorganisms" should be should be inserted after "products".
Pseudo Mark
MICRO BACK
Classification
International Classes
005